A Phase 1 Single Center, Open-Label, Randomized, Three-Way Crossover Study of the Relative Bioavailability of a Single Dose of CTP-656 in a Fasted, Fed Low-Fat and Fed Moderate-Fat Condition in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2016
At a glance
- Drugs Ivacaftor deuterated (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Concert Pharmaceuticals
- 27 Oct 2016 Results presented at 2016 North American Cystic Fibrosis Conference, as per Concert Pharmaceuticals media release.
- 27 Oct 2016 Results published in Concert Pharmaceuticals media release.
- 28 Apr 2016 Status changed from recruiting to completed, as reported by Concert Pharmaceuticals media release.